Neurocrine Biosciences
NBIX
#1644
Rank
S$17.01 B
Marketcap
S$169.17
Share price
3.77%
Change (1 day)
28.76%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$6.19

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$6.12. an increase over its 2024 EPS that were of S$4.29.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025S$5.9237.87%
2024S$4.2933.07%
2023S$3.2257.76%
2022S$2.0469.47%
2021S$1.21-78.21%
2020S$5.54990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.070.62%
2016S-$2.0657.28%
2015S-$1.3125.61%
2014S-$1.0418.84%
2013S-$0.88-1085.71%
2012S$0.08887

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.73-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$3.04-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$29.23 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$1.10-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.58-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.17-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$37.96-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.23-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK